Percentage of patients hospitalized for PAH as a first event occurring as part of the composite endpoint1
PAH-related hospitalizations are a key indicator of disease progression3,4
Proven in a Broad Range of Patients1
GRIPHON is the largest PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2
1156 Patients
UPTRAVI (selexipag):
n=574
Placebo: n=582
Mean age:
48 years
Female:
80%
1.4 Years (duration of exposure to UPTRAVI)
Longest endpoint evaluation period of any prostacyclin pathway therapy
0.9 Years
Median time from PAH diagnosis in patients taking UPTRAVI
New England Journal of Medicine Clinical Trial Publication for GRIPHON
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
Proven in a Broad Range of Patients1
GRIPHON is the largest PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2
1156 Patients
UPTRAVI (selexipag):
n=574
Placebo: n=582
Mean age:
48 years
Female:
80%
1.4 Years (duration of exposure
to UPTRAVI)
Longest endpoint evaluation period of any prostacyclin pathway therapy
0.9 Years
Median time from PAH diagnosis in patients taking UPTRAVI
New England Journal of Medicine Clinical Trial Publication for GRIPHON
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
